UCB (www.ucb.com) is a global biopharmaceutical Company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Headquartered in Brussels and operating in 40 countries with more than 9.000 employees, the Company represents a pillar of the European scientific excellence and international cooperation.
The commitment of UCB to innovation is paired with a robust sustainability strategy aiming for carbon neutrality. This combination of financial strength and social responsibility defines its leadership in the global life sciences sector.
In 2025 the Company generated a revenue of € 7.7 billion. UCB is listed on Euronext Brussels (symbol: UCB).
